CRIS Current Research Information System

PAPAYANNIDIS, CRISTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 22.500
NA - Nord America 21.539
EU - Europa 15.656
AF - Africa 1.342
SA - Sud America 1.239
Continente sconosciuto - Info sul continente non disponibili 1.169
OC - Oceania 33
Totale 63.478
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.053
VN - Vietnam 6.278
SG - Singapore 5.585
CN - Cina 5.499
GB - Regno Unito 3.976
IT - Italia 2.758
SE - Svezia 2.216
DE - Germania 1.829
HK - Hong Kong 1.423
IN - India 1.014
FR - Francia 976
BR - Brasile 880
RU - Federazione Russa 734
NL - Olanda 640
KR - Corea 533
IE - Irlanda 522
BD - Bangladesh 513
JP - Giappone 426
ZA - Sudafrica 384
FI - Finlandia 344
UA - Ucraina 317
TG - Togo 289
CA - Canada 270
EE - Estonia 270
CI - Costa d'Avorio 223
CH - Svizzera 210
GR - Grecia 181
NG - Nigeria 172
JO - Giordania 161
BG - Bulgaria 160
AR - Argentina 158
PH - Filippine 146
SC - Seychelles 136
IR - Iran 112
ID - Indonesia 107
IQ - Iraq 105
BE - Belgio 99
TR - Turchia 96
TH - Thailandia 94
PL - Polonia 89
ES - Italia 79
MX - Messico 78
AT - Austria 77
TW - Taiwan 64
UZ - Uzbekistan 55
PK - Pakistan 54
EC - Ecuador 48
SA - Arabia Saudita 38
MY - Malesia 35
VE - Venezuela 30
JM - Giamaica 29
LB - Libano 29
CL - Cile 28
AU - Australia 27
PY - Paraguay 27
HR - Croazia 26
EG - Egitto 25
CO - Colombia 24
TN - Tunisia 23
PE - Perù 22
CZ - Repubblica Ceca 21
MA - Marocco 20
CR - Costa Rica 19
LT - Lituania 19
RO - Romania 19
HN - Honduras 16
AE - Emirati Arabi Uniti 15
KE - Kenya 15
DZ - Algeria 14
KZ - Kazakistan 14
IL - Israele 13
RS - Serbia 13
EU - Europa 12
PT - Portogallo 12
TT - Trinidad e Tobago 12
ET - Etiopia 11
GT - Guatemala 11
NI - Nicaragua 11
NP - Nepal 11
OM - Oman 11
UY - Uruguay 11
AZ - Azerbaigian 10
MK - Macedonia 9
SK - Slovacchia (Repubblica Slovacca) 9
SV - El Salvador 9
TM - Turkmenistan 9
QA - Qatar 8
AL - Albania 7
KG - Kirghizistan 7
MU - Mauritius 7
PR - Porto Rico 7
BA - Bosnia-Erzegovina 6
GY - Guiana 6
NO - Norvegia 6
NZ - Nuova Zelanda 6
PA - Panama 6
PS - Palestinian Territory 6
BY - Bielorussia 5
DK - Danimarca 5
LV - Lettonia 5
Totale 62.229
Salva come PNG Salva come JPEG
Città #
Singapore 3.906
Southend 3.636
Ashburn 2.209
Chandler 1.628
San Jose 1.521
Fairfield 1.483
Dong Ket 1.344
Hong Kong 1.340
Ho Chi Minh City 1.197
Hanoi 1.012
Hefei 967
Houston 907
Beijing 852
Wilmington 795
Santa Clara 752
Woodbridge 737
Ann Arbor 709
Seattle 689
Princeton 652
Boardman 527
Dublin 517
Cambridge 514
Seoul 430
Bologna 428
Council Bluffs 417
New York 379
Lauterbourg 355
Los Angeles 330
Nanjing 322
Tokyo 322
Westminster 322
Lomé 289
Padova 284
Dallas 270
Helsinki 266
Medford 230
Milan 224
Abidjan 223
Buffalo 169
Bern 167
Frankfurt am Main 167
São Paulo 167
Haiphong 164
Shenyang 159
Amman 156
Sofia 154
Jinan 148
Da Nang 147
Berlin 143
Saint Petersburg 143
Munich 141
Redondo Beach 134
Redmond 126
Turin 126
Hebei 119
Rome 116
Nanchang 115
Abeokuta 111
Guangzhou 111
Bremen 105
San Diego 105
Shanghai 105
Changsha 104
Florence 96
Bengaluru 95
Brussels 93
Redwood City 90
Tianjin 85
Chicago 84
Zhengzhou 78
Falls Church 77
Jacksonville 76
Phoenix 75
Toronto 72
Jiaxing 71
Johannesburg 68
Amsterdam 65
Hải Dương 64
Biên Hòa 63
Hangzhou 62
Orem 61
London 57
Norwalk 57
Nuremberg 57
Baghdad 54
Jakarta 53
Falkenstein 51
Warsaw 50
Montreal 49
Vienna 47
Brooklyn 46
Can Tho 46
Hyderabad 44
Paris 44
Athens 43
Ningbo 43
Turku 43
Haikou 42
Atlanta 41
Mountain View 40
Totale 38.669
Salva come PNG Salva come JPEG
Nome #
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted 667
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery 409
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 358
A POLYMORPHISM IN THE CHROMOSOME 9P21 ANRIL LOCUS IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUSCEPTIBILITY 355
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 347
A NEW SUBSET OF ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENT WITH PREDNISONE-INDUCED MONOCYTIC DIFFERENTIATION? 346
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 326
A HIGH SENSITIVE NANOFLUIDIC ARRAY IMPROVES THE DETECTION OF RARE COPIES OF BCR-ABL1 TRANSCRIPT IN PATIENTS WITH PHILADELPHIA POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 323
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 320
Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia 318
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia 308
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 304
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 295
Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50 290
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 279
Co-occurrence of alterations in the DNA damage repair genes synergize with uncontrolled proliferation and associate with very-poor prognosis in acute myeloid leukemia patients 279
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 271
Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. 270
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 266
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia 261
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 259
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 259
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 257
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 256
A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia 254
Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis 253
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis 250
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 250
Susceptibility to Philadelphia-Positive acute Lymphoblastic Leukemia (ALL) Is Associated with a Germline Polymorphism In the ANRIL (CDKN2BAS) Locus. 250
CLINICAL OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/TLBL): THE BOLOGNA EXPERIENCE 248
Epigenetically induced ectopic expression of uncx impairs the proliferation and differentiation of myeloid cells 243
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 243
Novel and rare fusion transcripts involving transcription factors and tumor suppressor genes in acute myeloid leukemia 242
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia 242
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia 241
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 240
Optimized pipeline of MuTect and GATK tools to improve the detection of somatic single nucleotide polymorphisms in whole-exome sequencing data 238
Identification of A Pharmacogenomic Profile Associated with High Sensitivity and Low Toxicity to a Combination of Gemtuzumab Ozogamicin Plus Fludarabine, Cytarabine, Idarubicin Regimen In CD33-Positive Acute Myeloid Leukemia (AML) Patients 237
A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma 235
Chromothripsis in AML patients: A new mechanism of cancer initiation and progression 235
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 234
Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Patients with Coronary Artery Disease and in Centenarians. Further Clues Linking Chip with Cardiovascular Risk 234
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 234
WHOLE TRANSCRIPTOME DEEP-SEQUENCING IDENTIFIES NOVEL POINT MUTATIONS, GENE EXPRESSION AND ALTERNATIVE SPLICING PROFILES IN BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA 233
Flai (fludarabine, cytarabine, idarubicin) plus low-dose gemtuzumab ozogamicin as induction therapy in cd33-positive aml: Final results and long term outcome of a phase ii multicenter clinical trial 232
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 232
A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia 232
Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study 231
Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration 231
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 230
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF BY GENOMIC DELETIONS IS A FREQUENT EVENT IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS AND CONTRIBUTES TO DISEASE PROGRESSION 226
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 226
Safety Run-In and Part 1 of GIMEMA AML1718: Venetoclax Combined with FLAI as Induction Treatment in Non-Low-Risk AML 225
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 225
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 224
A case report of acute myeloid leukemia and neurofibromatosis 1 223
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 223
Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients 223
Use of a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript In Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL). 222
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations 221
AZACITIDINE IN HIGH AND LOW RISK MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF 57 PATIENTS TREATED WITH 4 DIFFERENT THERAPEUTIC REGIMENS 221
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 220
The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients 219
Inhibition of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) is a novel therapeutic strategy in B- and T-Acute Lymphoblastic Leukemia (ALL). 218
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF IS FREQUENTLY DELETED BUT NOT MUTATED IN BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS 218
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 217
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 215
Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia 215
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report 214
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents 213
Clustering Adult ACUTE Lymphoblastic Leukemia (ALL) Philadelphia Negative (Ph-) By Whole Exome Sequencing (WES) Analysis 213
Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities 213
Copy number variants signature in two patients with relapsed acute promyelocytic leukemia 212
Ultra-deep sequencing (uds) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis 212
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 212
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 211
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations 210
Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia 210
A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1 210
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents 208
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort 208
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS 207
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 206
Patologic IL 17 Producing Helper T Cells In Acute Myeloid Leukemia Patients 206
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 205
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. 204
BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients Treated with Only TKI Vs Conventional Chemo Plus TKI Therapy Show Similar DNA Alterations At Relapse Targeting Key Regulators of Tumor Suppression, Cell Cycle Control, and Lymphoid/B-Cell Development 204
Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis 204
A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure 204
ACTIVATION-INDUCED CYTIDINE DEAMINASE IS ABERRANTLY OVEREXPRESSED IN BCRABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS AND PROMOTES DNA-SINGLE STRAND BREAKS 203
Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia 202
Low-Dose Anti-T Lymphoglobulin as Prophylaxis for Graft-versus-Host Disease in Unrelated Donor Transplantations for Acute Leukemias and Myelodysplastic Syndromes. 202
EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE 202
INO‐CD22: A multicenter, real‐world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia 201
BCR-ABL1 transcript detection in patients with Philadelphia-positive Acute Lymphoblastic Leukemia (ALL) using a new and high sensitive nanofluidic method 201
Bromodomain Inhibition Is Effective Against Acute Myeloid Leukemia Cells Under Hypoxia and Induces Genome-Dependent Metabolic Perturbations 201
Donor Natural Killer (NK) Alloreactivity Predicts Long-Term Relapse-Free Survival in Acute Myeloid Leukemia Patients Undergoing Immunotherapy with NK Cells 200
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 198
Ponatinib as a Prophylactic or Pre-Emptive Strategy to Prevent Cytological Relapse after Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Transplanted in Complete Cytological Remission 197
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis 197
Totale 24.418
Salva come PNG Salva come JPEG
Categoria #
all - tutte 166.040
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 166.040
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20225.950 0 150 411 589 662 437 133 424 345 463 1.165 1.171
2022/20237.099 819 1.088 361 913 531 518 248 399 1.146 159 554 363
2023/20241.999 94 294 109 184 133 422 120 142 119 129 134 119
2024/20258.360 325 1.244 660 537 1.144 392 745 271 113 756 482 1.691
2025/202621.878 1.805 2.536 1.707 1.413 2.057 1.093 1.937 947 4.585 1.851 1.056 891
2026/20271.487 654 833 0 0 0 0 0 0 0 0 0 0
Totale 63.478